"10.1371_journal.pone.0071508","plos one","2013-08-27T00:00:00Z","Wei Xu; Lara Lacerda; Bisrat G Debeb; Rachel L Atkinson; Travis N Solley; Li Li; Darren Orton; John S McMurray; Brian I Hang; Ethan Lee; Ann H Klopp; Naoto T Ueno; James M Reuben; Savitri Krishnamurthy; Wendy A Woodward","Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; StemSynergy Therapeutics, Inc., Lauderdale by the Sea, Florida, United States of America; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Cell and Developmental Biology, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America; Division of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America","Conceived and designed the experiments: WX WW. Performed the experiments: WX L. Lacerda TS L. Li SK. Analyzed the data: WX L. Lacerda RLA. Contributed reagents/materials/analysis tools: DO BIH EL. Wrote the paper: WX WW EL JSM. Gave advice in experiments: BGD AK NTU JMR.","Darren Otron and Ethan Lee discloses competing financial interests: Ethan Lee is cofounder of StemSynergy Therapeutics Inc., a company that aims to develop inhibitors of major signaling pathways (including the Wnt pathway) as potential chemotherapeutic agents. Darren Orton is an employee of StemSynergy Therapeutics Inc. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","08","Wei Xu","WX",15,TRUE,2,2,2,4,TRUE,TRUE,TRUE,2,"5;14",TRUE
